{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,7]],"date-time":"2026-07-07T03:05:12Z","timestamp":1783393512672,"version":"3.54.6"},"reference-count":65,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2022,7,1]],"date-time":"2022-07-01T00:00:00Z","timestamp":1656633600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,7,1]],"date-time":"2022-07-01T00:00:00Z","timestamp":1656633600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,8,18]],"date-time":"2023-08-18T00:00:00Z","timestamp":1692316800000},"content-version":"vor","delay-in-days":413,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":["neurotherapeuticsjournal.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Neurotherapeutics"],"published-print":{"date-parts":[[2022,7]]},"DOI":"10.1007\/s13311-022-01252-5","type":"journal-article","created":{"date-parts":[[2022,6,6]],"date-time":"2022-06-06T12:03:07Z","timestamp":1654516987000},"page":"1216-1228","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":17,"title":["Does Ocrelizumab Limit Multiple Sclerosis Progression? Current Evidence from Clinical, MRI, and Fluid Biomarkers"],"prefix":"10.1016","volume":"19","author":[{"given":"Monica","family":"Margoni","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paolo","family":"Preziosa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paola","family":"Tortorella","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Massimo","family":"Filippi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2358-4320","authenticated-orcid":false,"given":"Maria A.","family":"Rocca","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1007\/s13311-022-01252-5_bib1","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1038\/s41572-018-0041-4","article-title":"Multiple sclerosis","volume":"4","author":"Filippi","year":"2018","journal-title":"Nat Rev Dis Primers"},{"issue":"3","key":"10.1007\/s13311-022-01252-5_bib2","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1056\/NEJMoa1601277","article-title":"Ocrelizumab versus interferon beta-1a in relapsing multiple sclerosis","volume":"376","author":"Hauser","year":"2017","journal-title":"N Engl J Med"},{"issue":"3","key":"10.1007\/s13311-022-01252-5_bib3","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1056\/NEJMoa1606468","article-title":"Ocrelizumab versus placebo in primary progressive multiple sclerosis","volume":"376","author":"Montalban","year":"2017","journal-title":"N Engl J Med"},{"issue":"4","key":"10.1007\/s13311-022-01252-5_bib4","doi-asserted-by":"crossref","first-page":"742","DOI":"10.1016\/j.neuron.2018.01.021","article-title":"Multiple sclerosis: mechanisms and immunotherapy","volume":"97","author":"Baecher-Allan","year":"2018","journal-title":"Neuron"},{"issue":"7","key":"10.1007\/s13311-022-01252-5_bib5","doi-asserted-by":"crossref","first-page":"696","DOI":"10.1038\/s41590-018-0135-x","article-title":"Reassessing B cell contributions in multiple sclerosis","volume":"19","author":"Li","year":"2018","journal-title":"Nat Immunol"},{"issue":"12","key":"10.1007\/s13311-022-01252-5_bib6","doi-asserted-by":"crossref","first-page":"905","DOI":"10.1038\/s41573-019-0035-2","article-title":"Progressive multiple sclerosis: from pathophysiology to therapeutic strategies","volume":"18","author":"Faissner","year":"2019","journal-title":"Nat Rev Drug Discov"},{"issue":"9","key":"10.1007\/s13311-022-01252-5_bib7","doi-asserted-by":"crossref","first-page":"1132","DOI":"10.1001\/jamaneurol.2020.1568","article-title":"Contribution of relapse-independent progression vs relapse-associated worsening to overall confirmed disability accumulation in typical relapsing multiple sclerosis in a pooled analysis of 2 randomized clinical trials","volume":"77","author":"Kappos","year":"2020","journal-title":"JAMA Neurol"},{"issue":"4","key":"10.1007\/s13311-022-01252-5_bib8","doi-asserted-by":"crossref","first-page":"835","DOI":"10.1007\/s13311-017-0557-4","article-title":"Ocrelizumab and Other CD20(+) B-cell-depleting therapies in multiple sclerosis","volume":"14","author":"Gelfand","year":"2017","journal-title":"Neurotherapeutics"},{"issue":"12","key":"10.1007\/s13311-022-01252-5_bib9","doi-asserted-by":"crossref","first-page":"5098","DOI":"10.1172\/JCI70972","article-title":"The mechanism of anti-CD20-mediated B cell depletion revealed by intravital imaging","volume":"123","author":"Montalvao","year":"2013","journal-title":"J Clin Invest"},{"issue":"9805","key":"10.1007\/s13311-022-01252-5_bib10","doi-asserted-by":"crossref","first-page":"1779","DOI":"10.1016\/S0140-6736(11)61649-8","article-title":"Ocrelizumab in relapsing-remitting multiple sclerosis: a phase 2, randomised, placebo-controlled, multicentre trial","volume":"378","author":"Kappos","year":"2011","journal-title":"Lancet"},{"issue":"11","key":"10.1007\/s13311-022-01252-5_bib11","doi-asserted-by":"crossref","first-page":"1444","DOI":"10.1212\/WNL.33.11.1444","article-title":"Rating neurologic impairment in multiple sclerosis: an expanded disability status scale (EDSS)","volume":"33","author":"Kurtzke","year":"1983","journal-title":"Neurology"},{"issue":"Pt 11","key":"10.1007\/s13311-022-01252-5_bib12","doi-asserted-by":"crossref","first-page":"3287","DOI":"10.1093\/brain\/awv258","article-title":"Defining reliable disability outcomes in multiple sclerosis","volume":"138","author":"Kalincik","year":"2015","journal-title":"Brain"},{"issue":"Pt 9","key":"10.1007\/s13311-022-01252-5_bib13","doi-asserted-by":"crossref","first-page":"2395","DOI":"10.1093\/brain\/aww173","article-title":"Defining secondary progressive multiple sclerosis","volume":"139","author":"Lorscheider","year":"2016","journal-title":"Brain"},{"issue":"1","key":"10.1007\/s13311-022-01252-5_bib14","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1177\/1352458516638941","article-title":"The EDSS-Plus, an improved endpoint for disability progression in secondary progressive multiple sclerosis","volume":"23","author":"Cadavid","year":"2017","journal-title":"Mult Scler"},{"issue":"21","key":"10.1007\/s13311-022-01252-5_bib15","doi-asserted-by":"crossref","first-page":"e1921","DOI":"10.1212\/WNL.0000000000008519","article-title":"Evaluation of multiple sclerosis disability outcome measures using pooled clinical trial data","volume":"93","author":"Goldman","year":"2019","journal-title":"Neurology"},{"issue":"16","key":"10.1007\/s13311-022-01252-5_bib16","doi-asserted-by":"crossref","first-page":"e1560","DOI":"10.1212\/WNL.0000000000012690","article-title":"Comparison of the EDSS, timed 25-foot walk, and the 9-hole peg test as clinical trial outcomes in relapsing-remitting multiple sclerosis","volume":"97","author":"Koch","year":"2021","journal-title":"Neurology"},{"issue":"1","key":"10.1007\/s13311-022-01252-5_bib17","doi-asserted-by":"crossref","first-page":"e111","DOI":"10.1212\/WNL.0000000000011123","article-title":"Reliability of outcome measures in clinical trials in secondary progressive multiple sclerosis","volume":"96","author":"Koch","year":"2021","journal-title":"Neurology"},{"issue":"3","key":"10.1007\/s13311-022-01252-5_bib18","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1007\/s40263-017-0412-5","article-title":"Outcome measures in clinical trials for multiple sclerosis","volume":"31","author":"van Munster","year":"2017","journal-title":"CNS Drugs"},{"issue":"6","key":"10.1007\/s13311-022-01252-5_bib19","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1007\/s40263-018-0530-8","article-title":"Disability outcome measures in phase III clinical trials in multiple sclerosis","volume":"32","author":"Uitdehaag","year":"2018","journal-title":"CNS Drugs"},{"key":"10.1007\/s13311-022-01252-5_bib20","doi-asserted-by":"crossref","unstructured":"Margoni M, Preziosa P, Filippi M, Rocca MA. Anti-CD20 therapies for multiple sclerosis: current status and future perspectives. J Neurol. 2021.","DOI":"10.1007\/s00415-021-10744-x"},{"issue":"12","key":"10.1007\/s13311-022-01252-5_bib21","doi-asserted-by":"crossref","first-page":"998","DOI":"10.1016\/S1474-4422(20)30342-2","article-title":"Long-term follow-up from the ORATORIO trial of ocrelizumab for primary progressive multiple sclerosis: a post-hoc analysis from the ongoing open-label extension of the randomised, placebo-controlled, phase 3 trial","volume":"19","author":"Wolinsky","year":"2020","journal-title":"Lancet Neurol"},{"issue":"2_suppl","key":"10.1007\/s13311-022-01252-5_bib22","first-page":"606","article-title":"Long-term reduction of relapse rate and confirmed disability progression after 7.5 years of ocrelizumab treatment in patients with relapsing multiple sclerosis in the OPERA OLE","volume":"27","author":"Giovannoni","year":"2021","journal-title":"Mult Scler J"},{"issue":"2_suppl","key":"10.1007\/s13311-022-01252-5_bib23","first-page":"101","article-title":"Sustained reduction in 48-week confirmed disability progression in patients with PPMS treated with ocrelizumab in the ORATORIO OLE: 8-year follow-up","volume":"27","author":"Wolinsky","year":"2021","journal-title":"Mult Scler J"},{"issue":"4","key":"10.1007\/s13311-022-01252-5_bib24","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1002\/ana.25313","article-title":"Evaluation of no evidence of progression or active disease (NEPAD) in patients with primary progressive multiple sclerosis in the ORATORIO trial","volume":"84","author":"Wolinsky","year":"2018","journal-title":"Ann Neurol"},{"issue":"5","key":"10.1007\/s13311-022-01252-5_bib25","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1002\/ana.25463","article-title":"Silent progression in disease activity-free relapsing multiple sclerosis","volume":"85","author":"University of California SFMSET","year":"2019","journal-title":"Ann Neurol"},{"key":"10.1007\/s13311-022-01252-5_bib26","doi-asserted-by":"crossref","unstructured":"Lublin FD, Haring DA, Ganjgahi H, Ocampo A, Hatami F, Cuklina J, et al. How patients with multiple sclerosis acquire disability. Brain. 2022.","DOI":"10.1093\/brain\/awac016"},{"key":"10.1007\/s13311-022-01252-5_bib27","doi-asserted-by":"crossref","unstructured":"Chan A, Phillips JT, Fox R, Zhang A, Potts J, Kurukulasuriya N, editors. Differential recovery from relapse between treatment groups in the CONFIRM study of delayed-release dimethyl fumarate (P7.215). AAN; 2015: https:\/\/n.neurology.org\/content\/84\/14_Supplement\/P7.215 Poster P7.215. Accessed 8 Nov 2021.","DOI":"10.1212\/WNL.84.14_supplement.P7.215"},{"issue":"5","key":"10.1007\/s13311-022-01252-5_bib28","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1177\/1352458520926869","article-title":"Real-world disability improvement in patients with relapsing-remitting multiple sclerosis treated with natalizumab in the Tysabri Observational Program","volume":"27","author":"Wiendl","year":"2021","journal-title":"Mult Scler"},{"issue":"8","key":"10.1007\/s13311-022-01252-5_bib29","doi-asserted-by":"crossref","first-page":"970","DOI":"10.1177\/1352458511399611","article-title":"Sustained improvement in Expanded Disability Status Scale as a new efficacy measure of neurological change in multiple sclerosis: treatment effects with natalizumab in patients with relapsing multiple sclerosis","volume":"17","author":"Phillips","year":"2011","journal-title":"Mult Scler"},{"issue":"3","key":"10.1007\/s13311-022-01252-5_bib30","doi-asserted-by":"crossref","first-page":"438","DOI":"10.1002\/ana.25808","article-title":"Identifying progression in multiple sclerosis: new perspectives","volume":"88","author":"Filippi","year":"2020","journal-title":"Ann Neurol"},{"issue":"10","key":"10.1007\/s13311-022-01252-5_bib31","doi-asserted-by":"crossref","first-page":"860","DOI":"10.1016\/S1474-4422(20)30277-5","article-title":"Cognitive impairment in multiple sclerosis: clinical management, MRI, and therapeutic avenues","volume":"19","author":"Benedict","year":"2020","journal-title":"Lancet Neurol"},{"issue":"3","key":"10.1007\/s13311-022-01252-5_bib32","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1016\/S1474-4422(14)70250-9","article-title":"Clinical and imaging assessment of cognitive dysfunction in multiple sclerosis","volume":"14","author":"Rocca","year":"2015","journal-title":"Lancet Neurol"},{"key":"10.1007\/s13311-022-01252-5_bib33","doi-asserted-by":"crossref","unstructured":"Preziosa P, Conti L, Rocca MA, Filippi M. Effects on cognition of DMTs in multiple sclerosis: moving beyond the prevention of inflammatory activity. J Neurol. 2021.","DOI":"10.1007\/s00415-021-10832-y"},{"key":"10.1007\/s13311-022-01252-5_bib34","doi-asserted-by":"crossref","unstructured":"Benedict R, De Seze J, Hauser S, Kappos L, Wolinsky J, Zheng H, et al., editors. Impact of ocrelizumab on cognition in patients at increased risk of progressive disease (P1.420). AAN; 2018: https:\/\/n.neurology.org\/content\/90\/15_Supplement\/P1.420 Poster P1.420. Accessed 8 Nov 2021.","DOI":"10.1212\/WNL.90.15_supplement.P1.420"},{"key":"10.1007\/s13311-022-01252-5_bib35","doi-asserted-by":"crossref","unstructured":"Cohan S, Benedict R, De Seze J, Hauser S, Kappos L, Wolinsky J, et al., editors. Time to cognitive worsening in patients with relapsing multiple sclerosis in ocrelizumab phase III trials (S44.005). AAN; 2018: https:\/\/n.neurology.org\/content\/90\/15_Supplement\/S44.005 Platform Presentation S44.005. Accessed 8 Nov 2021.","DOI":"10.1212\/WNL.90.15_supplement.S44.005"},{"issue":"1","key":"10.1007\/s13311-022-01252-5_bib36","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1177\/1352458519898108","article-title":"Recovery of cognitive function after relapse in multiple sclerosis","volume":"27","author":"Benedict","year":"2021","journal-title":"Mult Scler"},{"issue":"18 Supplement","key":"10.1007\/s13311-022-01252-5_bib37","doi-asserted-by":"crossref","first-page":"647","DOI":"10.1212\/WNL.98.18_supplement.647","article-title":"A multicenter, open label, single-arm, phase 3b study (CONSONANCE) to assess efficacy of ocrelizumab in patients with primary and secondary progressive multiple sclerosis: year 1 interim analysis of cognition outcomes (P1\u20131.Virtual)","volume":"98","author":"Benedict","year":"2022","journal-title":"Neurology"},{"issue":"12","key":"10.1007\/s13311-022-01252-5_bib38","doi-asserted-by":"crossref","first-page":"1338","DOI":"10.1111\/j.1468-1331.2007.01974.x","article-title":"A prospective study of patterns of fatigue in multiple sclerosis","volume":"14","author":"Lerdal","year":"2007","journal-title":"Eur J Neurol"},{"issue":"6","key":"10.1007\/s13311-022-01252-5_bib39","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1097\/00005650-199206000-00002","article-title":"The MOS 36-item short-form health survey (SF-36). I. Conceptual framework and item selection","volume":"30","author":"Ware","year":"1992","journal-title":"Med Care"},{"issue":"2","key":"10.1007\/s13311-022-01252-5_bib40","article-title":"The impact of ocrelizumab on health-related quality of life in individuals with multiple sclerosis","volume":"7","author":"Glanz","year":"2021","journal-title":"Mult Scler J Exp Transl Clin"},{"issue":"1","key":"10.1007\/s13311-022-01252-5_bib41","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1007\/s40120-020-00224-1","article-title":"Work productivity outcomes associated with ocrelizumab compared with other disease-modifying therapies for multiple sclerosis","volume":"10","author":"Neuberger","year":"2021","journal-title":"Neurol Ther"},{"issue":"8","key":"10.1007\/s13311-022-01252-5_bib42","doi-asserted-by":"crossref","first-page":"747","DOI":"10.1080\/14737175.2020.1760846","article-title":"Current state-of-art of the application of serum neurofilaments in multiple sclerosis diagnosis and monitoring","volume":"20","author":"Preziosa","year":"2020","journal-title":"Expert Rev Neurother"},{"issue":"11","key":"10.1007\/s13311-022-01252-5_bib43","doi-asserted-by":"crossref","first-page":"e1201","DOI":"10.1212\/WNL.0000000000009097","article-title":"Blood neurofilament light levels segregate treatment effects in multiple sclerosis","volume":"94","author":"Delcoigne","year":"2020","journal-title":"Neurology"},{"key":"10.1007\/s13311-022-01252-5_bib44","doi-asserted-by":"crossref","unstructured":"Cross A, Bennett J, von B\u00fcdingen HC, Carruthers R, Edwards K, Fallis R, et al., editors. Ocrelizumab treatment reduced levels of neurofilament light chain and numbers of B cells in the cerebrospinal fluid of patients with relapsing multiple sclerosis in the OBOE study (S56.008). AAN; 2019. https:\/\/n.neurology.org\/content\/92\/15_Supplement\/S56.008 Platform Presentation S56.008. Accessed 8 Nov 2021.","DOI":"10.1212\/WNL.92.15_supplement.S56.008"},{"key":"10.1007\/s13311-022-01252-5_bib45","doi-asserted-by":"crossref","unstructured":"Bar-Or A, Thanei G, Harp C, Bernasconi C, Bonati U, Cross AH, et al., editors. Ocrelizumab treatment induces a sustained blood NfL reduction in patients with PPMS and RMS. Mult Scler J 2020; 26 (S3): 178-179. ECTRIMS; 2020: MSVirtual 2020\u2014Poster Abstracts P0125. Accessed 8 Nov 2021. https:\/\/journals.sagepub.com\/doi\/full\/10.1177\/1352458520974937","DOI":"10.1177\/1352458520974937"},{"key":"10.1007\/s13311-022-01252-5_bib46","unstructured":"Bar-Or A, Thanei G, Harp C, Bernasconi C, Bonati U, Cross AH, et al., editors. Blood neurofilament light levels are lowered to a healthy donor range in patients with RMS and PPMS following ocrelizumab treatment. Mult Scler J 2019; 25 (S2): 52. ECTRIMS 2019\u2014Oral Presentations 152. Accessed 8 Nov 2021. https:\/\/journals.sagepub.com\/doi\/10.1177\/1352458519868070"},{"issue":"4","key":"10.1007\/s13311-022-01252-5_bib47","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1212\/WNL.0000000000003542","article-title":"Brain MRI atrophy quantification in MS: from methods to clinical application","volume":"88","author":"Rocca","year":"2017","journal-title":"Neurology"},{"issue":"3","key":"10.1007\/s13311-022-01252-5_bib48","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1038\/s41582-020-0314-x","article-title":"MAGNIMS consensus recommendations on the use of brain and spinal cord atrophy measures in clinical practice","volume":"16","author":"Sastre-Garriga","year":"2020","journal-title":"Nat Rev Neurol"},{"issue":"3","key":"10.1007\/s13311-022-01252-5_bib49","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1097\/WCO.0000000000000095","article-title":"Magnetic resonance outcome measures in multiple sclerosis trials: time to rethink?","volume":"27","author":"Filippi","year":"2014","journal-title":"Curr Opin Neurol"},{"issue":"9","key":"10.1007\/s13311-022-01252-5_bib50","doi-asserted-by":"crossref","first-page":"835","DOI":"10.1080\/14737175.2019.1555038","article-title":"Application of advanced MRI techniques to monitor pharmacologic and rehabilitative treatment in multiple sclerosis: current status and future perspectives","volume":"19","author":"Rocca","year":"2019","journal-title":"Expert Rev Neurother"},{"issue":"1","key":"10.1007\/s13311-022-01252-5_bib51","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1002\/ana.24018","article-title":"Treatment effect on brain atrophy correlates with treatment effect on disability in multiple sclerosis","volume":"75","author":"Sormani","year":"2014","journal-title":"Ann Neurol"},{"issue":"13","key":"10.1007\/s13311-022-01252-5_bib52","doi-asserted-by":"crossref","first-page":"e1854","DOI":"10.1212\/WNL.0000000000010376","article-title":"Five years of ocrelizumab in relapsing multiple sclerosis: OPERA studies open-label extension","volume":"95","author":"Hauser","year":"2020","journal-title":"Neurology"},{"issue":"2","key":"10.1007\/s13311-022-01252-5_bib53","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1002\/ana.25145","article-title":"Deep gray matter volume loss drives disability worsening in multiple sclerosis","volume":"83","author":"Eshaghi","year":"2018","journal-title":"Ann Neurol"},{"issue":"2","key":"10.1007\/s13311-022-01252-5_bib54","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1002\/ana.25150","article-title":"Thalamic atrophy in multiple sclerosis: a magnetic resonance imaging marker of neurodegeneration throughout disease","volume":"83","author":"Azevedo","year":"2018","journal-title":"Ann Neurol"},{"key":"10.1007\/s13311-022-01252-5_bib55","unstructured":"Bar-Or A, Thanei G, Harp C, Bernasconi C, Bonati U, Cross AH, et al. Ocrelizumab reduces thalamic volume loss and clinical progression in ppms and rms independent of baseline nfl and other measures of disease severity. Mult Scler J 2020; 26 (S3): 177. ECTRIMS: MSVirtual 2020\u2014Poster Abstracts P0123. Accessed 8 Nov 2021. https:\/\/journals.sagepub.com\/doi\/full\/10.1177\/1352458520974937"},{"key":"10.1007\/s13311-022-01252-5_bib56","unstructured":"Arnold D, Sprenger T, Bar-Or A, Wolinsky J, Kappos L, Kolind S, et al. editors. Reduced thalamic atrophy in patients initiating earlier versus delayed ocrelizumab therapy: results from the OLE of OPERA I\/II and ORATORIO. Mult Scler J 2020; 26 (S3): 8-9. ECTRIMS; 2020: MSVirtual 2020\u2014Platform Presentations FC03.05. Accessed 8 Nov 2021. https:\/\/journals.sagepub.com\/doi\/full\/10.1177\/1352458520974936"},{"issue":"5","key":"10.1007\/s13311-022-01252-5_bib57","doi-asserted-by":"crossref","first-page":"710","DOI":"10.1002\/ana.24497","article-title":"Clinical and pathological insights into the dynamic nature of the white matter multiple sclerosis plaque","volume":"78","author":"Frischer","year":"2015","journal-title":"Ann Neurol"},{"issue":"4","key":"10.1007\/s13311-022-01252-5_bib58","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1007\/s00401-018-1818-y","article-title":"Progressive multiple sclerosis patients show substantial lesion activity that correlates with clinical disease severity and sex: a retrospective autopsy cohort analysis","volume":"135","author":"Luchetti","year":"2018","journal-title":"Acta Neuropathol"},{"issue":"1","key":"10.1007\/s13311-022-01252-5_bib59","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1007\/s00401-016-1636-z","article-title":"Slow expansion of multiple sclerosis iron rim lesions: pathology and 7 T magnetic resonance imaging","volume":"133","author":"Dal-Bianco","year":"2017","journal-title":"Acta Neuropathol"},{"issue":"3","key":"10.1007\/s13311-022-01252-5_bib60","doi-asserted-by":"crossref","first-page":"833","DOI":"10.1093\/brain\/awaa436","article-title":"Long-term evolution of multiple sclerosis iron rim lesions in 7 T MRI","volume":"144","author":"Dal-Bianco","year":"2021","journal-title":"Brain"},{"issue":"3","key":"10.1007\/s13311-022-01252-5_bib61","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1001\/jamaneurol.2020.4689","article-title":"Diagnosis of progressive multiple sclerosis from the imaging perspective: a review","volume":"78","author":"Filippi","year":"2021","journal-title":"JAMA Neurol"},{"issue":"8","key":"10.1007\/s13311-022-01252-5_bib62","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1080\/14737175.2021.1953983","article-title":"Chronic active lesions: a new MRI biomarker to monitor treatment effect in multiple sclerosis?","volume":"21","author":"Preziosa","year":"2021","journal-title":"Expert Rev Neurother"},{"issue":"9","key":"10.1007\/s13311-022-01252-5_bib63","doi-asserted-by":"crossref","first-page":"2787","DOI":"10.1093\/brain\/awz212","article-title":"Chronic white matter lesion activity predicts clinical progression in primary progressive multiple sclerosis","volume":"142","author":"Elliott","year":"2019","journal-title":"Brain"},{"issue":"14","key":"10.1007\/s13311-022-01252-5_bib64","doi-asserted-by":"crossref","first-page":"1915","DOI":"10.1177\/1352458518814117","article-title":"Slowly expanding\/evolving lesions as a magnetic resonance imaging marker of chronic active multiple sclerosis lesions","volume":"25","author":"Elliott","year":"2019","journal-title":"Mult Scler"},{"key":"10.1007\/s13311-022-01252-5_bib65","doi-asserted-by":"crossref","unstructured":"Preziosa P, Pagani E, Moiola L, Rodegher M, Filippi M, Rocca MA. Occurrence and microstructural features of slowly expanding lesions on fingolimod or natalizumab treatment in multiple sclerosis. Mult Scler. 2020:1352458520969105.","DOI":"10.1177\/1352458520969105"}],"container-title":["Neurotherapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13311-022-01252-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s13311-022-01252-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1878747923010772?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1878747923010772?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13311-022-01252-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,30]],"date-time":"2025-10-30T06:55:28Z","timestamp":1761807328000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1878747923010772"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,7]]},"references-count":65,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2022,7]]}},"alternative-id":["S1878747923010772"],"URL":"https:\/\/doi.org\/10.1007\/s13311-022-01252-5","relation":{},"ISSN":["1878-7479"],"issn-type":[{"value":"1878-7479","type":"print"}],"subject":[],"published":{"date-parts":[[2022,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Does Ocrelizumab Limit Multiple Sclerosis Progression? Current Evidence from Clinical, MRI, and Fluid Biomarkers","name":"articletitle","label":"Article Title"},{"value":"Neurotherapeutics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1007\/s13311-022-01252-5","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2022 The American Society for Experimental NeuroTherapeutics, Inc. Published by Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}